Insider Selling: Insmed (NASDAQ:INSM) CEO Sells 10,699 Shares of Stock

Insmed, Inc. (NASDAQ:INSM) CEO William Lewis sold 10,699 shares of Insmed stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $143.52, for a total value of $1,535,520.48. Following the sale, the chief executive officer directly owned 301,185 shares in the company, valued at approximately $43,226,071.20. The trade was a 3.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

William Lewis also recently made the following trade(s):

• On Thursday, March 5th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $146.03, for a total value of $1,562,374.97.
• On Thursday, February 19th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $150.97, for a total value of $1,615,228.03.
• On Monday, February 9th, William Lewis sold 13,396 shares of Insmed stock. The shares were sold at an average price of $147.79, for a total value of $1,979,794.84.
• On Tuesday, February 3rd, William Lewis sold 3,009 shares of Insmed stock. The shares were sold at an average price of $156.34, for a total value of $470,427.06.
• On Tuesday, January 20th, William Lewis sold 10,699 shares of Insmed stock. The stock was sold at an average price of $158.93, for a total transaction of $1,700,392.07.
• On Monday, January 12th, William Lewis sold 19,215 shares of Insmed stock. The stock was sold at an average price of $169.00, for a total transaction of $3,247,335.00.
• On Thursday, January 8th, William Lewis sold 3,223 shares of Insmed stock. The shares were sold at an average price of $174.17, for a total transaction of $561,349.91.
• On Wednesday, January 7th, William Lewis sold 2,357 shares of Insmed stock. The shares were sold at an average price of $175.07, for a total transaction of $412,639.99.
• On Tuesday, January 6th, William Lewis sold 4,096 shares of Insmed stock. The stock was sold at an average price of $173.33, for a total transaction of $709,959.68.

Insmed Stock Down 5.6%

Shares of INSM traded down $8.00 during midday trading on Friday, hitting $136.00. The company had a trading volume of 1,365,912 shares, compared to its average volume of 2,390,861. The stock has a market cap of $29.31 billion, a price-to-earnings ratio of -21.22 and a beta of 1.13. The company’s 50 day moving average price is $152.75 and its 200 day moving average price is $165.96. The company has a quick ratio of 3.54, a current ratio of 3.83 and a debt-to-equity ratio of 0.76. Insmed, Inc. has a 52 week low of $60.40 and a 52 week high of $212.75.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) EPS for the quarter, missing the consensus estimate of ($1.07) by ($0.47). The company had revenue of $263.84 million for the quarter, compared to the consensus estimate of $263.97 million. Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The business’s revenue for the quarter was up 152.6% on a year-over-year basis. During the same period in the previous year, the business posted ($1.32) EPS. On average, equities research analysts predict that Insmed, Inc. will post -4.56 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Bank of America set a $203.00 price target on Insmed in a report on Thursday, December 18th. Morgan Stanley set a $166.00 price objective on shares of Insmed in a report on Friday, February 20th. Mizuho dropped their target price on shares of Insmed from $211.00 to $204.00 and set an “outperform” rating on the stock in a report on Tuesday, February 24th. HC Wainwright reaffirmed a “buy” rating and issued a $230.00 price target on shares of Insmed in a report on Monday, February 23rd. Finally, Leerink Partners reaffirmed an “outperform” rating on shares of Insmed in a research report on Thursday, December 18th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $205.57.

Hedge Funds Weigh In On Insmed

Hedge funds and other institutional investors have recently modified their holdings of the company. Hsbc Holdings PLC lifted its position in Insmed by 8,052.6% in the 4th quarter. Hsbc Holdings PLC now owns 123,267 shares of the biopharmaceutical company’s stock valued at $21,493,000 after purchasing an additional 121,755 shares during the last quarter. Rockefeller Capital Management L.P. increased its stake in shares of Insmed by 88.2% in the fourth quarter. Rockefeller Capital Management L.P. now owns 16,775 shares of the biopharmaceutical company’s stock valued at $2,920,000 after purchasing an additional 7,863 shares during the period. Corient Private Wealth LLC increased its stake in shares of Insmed by 34.1% in the fourth quarter. Corient Private Wealth LLC now owns 20,865 shares of the biopharmaceutical company’s stock valued at $3,631,000 after purchasing an additional 5,305 shares during the period. Keenan LLC bought a new stake in shares of Insmed during the fourth quarter valued at approximately $369,000. Finally, Reflection Asset Management bought a new stake in shares of Insmed during the fourth quarter valued at approximately $30,000.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.